Immunis: Funding, Investors & Team (Sep 2026)
Immunis is a private biotechnology company working on a new therapy for immune decline associated with aging and disease.
Immunis has raised $15.8M across 1 funding round on record, the most recent an undisclosed round of $15.8M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immunis Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Immunis Funding Rounds
Immunis Founders and Leadership Team
Contact details for the Immunis team: 1 of 1 has an email address on file.
Start 14-day free trial →Immunis Funding Compared to Other Biotechnology Startups
Immunis' latest round of $15.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immunis in Biotechnology and Irvine
Companies Similar to Immunis
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
Immunis Funding FAQs
What does Immunis do?
Immunis is a private biotechnology company working on a new therapy for immune decline associated with aging and disease.
How much funding has Immunis raised?
Immunis has raised $15.8M across 1 round on record. The most recent is an undisclosed round of $15.8M announced in Jul 2024.
When did Immunis last raise funding?
Immunis' most recent funding round on record is an undisclosed round of $15.8M, announced in Jul 2024.
Who founded Immunis?
FundedIQ lists Hans S Keirstead (Founder) at Immunis.
Where is Immunis headquartered?
Immunis is based in Irvine, California, United States.
How many employees does Immunis have?
Immunis is in the 11-50 employee band.
How does Immunis' funding compare to other Biotechnology startups?
Immunis' latest round of $15.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Immunis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immunis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.